Sino-American Crown Biotechnology (Taicang) Co Ltd, based in the Taicang High-Tech Zone, Taicang, a city in Suzhou, was recently selected as one of the inaugural members of the provincial-level digital trade platform.

A global contract research organization (CRO), the company specializes in pre-clinical and translational medical platform services. It plays a pivotal role in advancing research related to immunology and immune-mediated inflammatory diseases.

Leveraging world-class technology and operational systems and combined with China's human and resource advantages, the company offers a one-stop solution ranging from early target screening in drug development to clinical candidate compounds.

The company offers its services to pharmaceutical and biotech firms worldwide. Among its current clientele are top 20 global pharmaceutical companies and over 200 medium-sized biotech research enterprises.

Recognizing the pivotal role of key enterprises and platforms in advancing industrial development, the zone intends to optimize policies that help cultivate strengths in the biomedical research service and logistics transportation service sectors.

The provincial digital trade platform focuses on addressing the needs of the digital trade industry and enterprises. Using advanced technological means and a platform-based approach, it offers distinct advantages in platform operations, business scale, industrial empowerment, innovation capacity, and societal benefits.

Sino-American Crown Biotechnology (Taicang) Co Ltd. [Photo/WeChat account: gh_5d51cb296177]